The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.
 
Kersti Oselin
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; MSD; Roche; Takeda
Research Funding - Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD
 
Byoung Yong Shim
Consulting or Advisory Role - AstraZeneca; Bion; Guardant Health; J Ints Bio; Pfizer; Takeda
Research Funding - Yuhan
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Maciej Bryl
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche/Genentech; Takeda
 
Laura Bonanno
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; MSD Oncology; Novartis; Roche/Genentech
Speakers' Bureau - AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; Novartis/Ipsen
 
Guzin Demirag
No Relationships to Disclose
 
Ida Colantonio
No Relationships to Disclose
 
Martin Kimmich
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Merck; Takeda
Consulting or Advisory Role - AstraZeneca; Merck; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer
 
Urska Janzic
Honoraria - AstraZeneca; Boehringer Ingelheim; MSD Oncology; Pfizer; Roche; Takeda
 
Johan F. Vansteenkiste
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi-Sankyo (Inst); Janssen (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); PDC Line Pharma (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - MSD (Inst)
 
Reyes Bernabe Caro
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; MSD Oncology; Roche; Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Amina Scherz
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; MSD; Takeda
Research Funding - MSD (Inst)
Travel, Accommodations, Expenses - MSD; Pfizer; Roche/Genentech
 
Alessandra Curioni-Fontecedro
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Roche; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); MSD (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Martin Früh
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Research Funding - AstraZeneca; MSD
 
Mira Wollner
Honoraria - Novartis; Pfizer
Research Funding - Merck Sharp & Dohme (Inst)
 
Jing Yang
Employment - Merck
 
Nazly Shariati
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Sandrine Marreaud
No Relationships to Disclose
 
Solange Peters
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Fishawack Facilitate (Inst); Illumina (Inst); Imedex (Inst); Incyte (Inst); medscape (Inst); Medtoday (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); OncologyEducation (Inst); Peerview (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Biocartis (Inst); Bioinvent (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-Star Biotechnology (Inst); Foundation Medicine (Inst); Genzyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Incyte (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst); Vaccibody (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology (I); ESMO; ETOP Scientific chair; JTO Past Deputy Editor; SAMO President
 
Mary ER O'Brien
Employment - Oxford Biomedica (I)
Honoraria - Abbvie; Merck Serono; MSD
Consulting or Advisory Role - Eisai; iTEOS Therapeutics; Merck; PharmaMar; Pierre Fabre; Puma Biotechnology
Patents, Royalties, Other Intellectual Property - Fast facts NSCLC, Karger publisher Edition 1 and 2
Travel, Accommodations, Expenses - MSD